Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial - Goldberg, SB; Schalper, KA; Gettinger, SN (Lancet Oncol, 2020)
et al.